2100 West Loop South
Suite 900
Houston, TX 77027
United States
800 946 9185
https://www.cnspharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 3
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. John Michael Climaco Esq., J.D. | CEO, President & Director | 525k | N/D | 1969 |
Mr. Christopher S. Downs CPA, CTP, FP&A | Chief Financial Officer | 382.16k | N/D | 1979 |
Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer | 261.2k | N/D | 1955 |
Dr. Waldemar Priebe Ph.D. | Founder | N/D | N/D | N/D |
Dr. Donald H. Picker Ph.D. | Chief Science Officer | N/D | N/D | 1946 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
La calificación ISS Governance QuickScore de CNS Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.